Humacyte, Inc. (HUMA) company profile

Humacyte, Inc. is a biotechnology company focused on developing and commercializing bioengineered human acellular vessels and tissue engineering technologies. The company operates in program areas and reportable segments that include vascular trauma, arteriovenous (AV) access for hemodialysis, and peripheral arterial disease (PAD). Its medical technologies are targeted toward patients requiring vascular repair, replacement, or reconstruction across acute trauma care and vascular disease treatments.

The provided filing text comprises XBRL reporting taxonomy elements and accounting entries covering product categories, research and development activities, and collaborative relationships with institutions such as Yale University and Duke University. The document notes operations subject to state and local jurisdictions, but it does not disclose specific operational scale metrics, physical facility counts, country operations, or the location of corporate headquarters.

Summary of the business section of Humacyte's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“Each unit has an offering price of $10.00 and consists of one share of our Class A common stock and one -half of one redeemable warrant.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of December 31, 2025, we had 184 employees, all of whom were full-time.”